Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
National Cancer Institute (NCI)
SWOG Cancer Research Network
Rutgers, The State University of New Jersey
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Pheon Therapeutics
University of British Columbia
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Eli Lilly and Company
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Teclison Ltd.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
AstraZeneca
VA Office of Research and Development
Bristol-Myers Squibb
Medical University of South Carolina
ArriVent BioPharma, Inc.
Istanbul Medipol University Hospital
Achieve Life Sciences
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Iovance Biotherapeutics, Inc.
M.D. Anderson Cancer Center
Technische Universität Dresden
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Boehringer Ingelheim
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
BeOne Medicines
The Cooper Health System
City of Hope Medical Center
Kestrel Therapeutics, Inc.
Dana-Farber Cancer Institute
Boehringer Ingelheim
University of Utah
Zymeworks BC Inc.
Firat University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Montefiore Medical Center
Montefiore Medical Center